Kabir Nath
CEO of Compass Pathways, discussing the company's development of synthetic psilocybin as a potential treatment for depression and the regulatory pathway for approval.
Best podcasts with Kabir Nath
Ranked by the Snipd community
Aug 1, 2025 • 1h 27min
Bloomberg Businessweek Weekend - August 1st, 2025
Laura Martin, a senior analyst at Needham & Company, dives into the dynamics of the Mag7 stocks and market trends. Pascal Soriot, CEO of AstraZeneca, discusses the company's ambitious $50 billion investment in U.S. production and the competition with China. Kabir Nath, of Compass Pathways, shares insights into developing psilocybin for depression treatment. Meanwhile, Hannah Elliott explores the quirky Tesla Diner experience and its connection to key fobs. Ted Alcorn reveals Burning Man's financial struggles and cultural essence, highlighting the festival's complex financial landscape.
Jul 29, 2025 • 38min
US, China Agree to Continue Talks on Tariff Truce Extension
Joining the discussion are Oliver Crook, Bloomberg News Europe Correspondent, who shares insights on the latest U.S.-China tariff negotiations, and Brooke Sutherland, Boston Bureau Chief with a keen eye on industry trends. Kabir Nath, CEO of Compass Pathways, discusses the groundbreaking potential of synthetic psilocybin for treating depression. They dive into U.S.-China trade dynamics, the strategic interests at play, and the promising future of psychedelic therapy, highlighting both economic and mental health impacts.
